Dianthus Therapeutics (DNTH) Net Income towards Common Stockholders (2017 - 2025)

Dianthus Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$36.6 million for Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 31.78% year-over-year to -$36.6 million; the TTM figure through Dec 2025 stood at -$97.5 million (down 11.12% YoY), while the FY2024 annual figure was -$84.5 million, down 94.65% from the prior year.
• Net Income towards Common Stockholders was -$36.6 million for Q3 2025 at Dianthus Therapeutics, down from -$31.5 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$7.1 million in Q1 2023 to a low of -$36.6 million in Q3 2025.
• Historically, Net Income towards Common Stockholders has averaged -$18.8 million across 5 years, with a median of -$17.4 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 69.16% in 2023, then tumbled 165.66% in 2024.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$19.3 million in 2021, then jumped by 47.89% to -$10.1 million in 2022, then fell by 4.57% to -$10.5 million in 2023, then sank by 165.66% to -$27.9 million in 2024, then sank by 31.17% to -$36.6 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$36.6 million (Q3 2025), -$31.5 million (Q2 2025), and -$29.4 million (Q1 2025), per Business Quant data.